AAAAAA
Results: 26-45/45
Authors:
Camerlingo, M
Casto, L
Censori, B
Ferraro, B
Caverni, L
Manara, O
Finazzi, G
Radice, E
Drago, G
De Tommasi, SM
Gotti, E
Barbui, T
Mamoli, A
Citation: M. Camerlingo et al., Recurrence after first cerebral infarction in young adults, ACT NEUR SC, 102(2), 2000, pp. 87-93
Authors:
Chiodini, B
Bassan, R
Barbui, T
Citation: B. Chiodini et al., Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+human leukemic cells, LEUK LYMPH, 33(5-6), 1999, pp. 485-497
Authors:
Barbui, T
Finazzi, G
Citation: T. Barbui et G. Finazzi, Management of essential thrombocythemia, CR R ONC H, 29(3), 1999, pp. 257-266
Authors:
Finazzi, G
Barbui, T
Citation: G. Finazzi et T. Barbui, Treatment of essential thrombocythemia with special emphasis on leukemogenic risk, ANN HEMATOL, 78(9), 1999, pp. 389-392
Authors:
Cortelazzo, S
Rossi, A
Bellavita, P
Oldani, E
Viero, P
Buelli, M
Rambaldi, A
Barbui, T
Citation: S. Cortelazzo et al., Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI), ANN ONCOL, 10(4), 1999, pp. 427-432
Authors:
Cortelazzo, S
Rossi, A
Roggero, E
Oldani, E
Zucca, E
Tondini, C
Ambrosetti, A
Pasini, F
Pinotti, G
Bertini, M
Vitolo, U
Busetto, M
Gianni, L
Cavalli, F
Barbui, T
Citation: S. Cortelazzo et al., Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma, ANN ONCOL, 10(12), 1999, pp. 1433-1440
Authors:
Dotti, G
Fiocchi, R
Motta, T
Facchinetti, B
Chiodini, B
Borleri, GM
Gavazzeni, G
Barbui, T
Rambaldi, A
Citation: G. Dotti et al., Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8, LEUKEMIA, 13(5), 1999, pp. 664-670
Authors:
Foran, JM
Rohatiner, AZS
Coiffier, B
Barbui, T
Johnson, SA
Hiddemann, W
Radford, JA
Norton, AJ
Tollerfield, SM
Wilson, MP
Lister, TA
Citation: Jm. Foran et al., Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma, J CL ONCOL, 17(2), 1999, pp. 546-553
Authors:
Bassan, R
Pogliani, E
Lerede, J
Fabris, P
Rossi, G
Morandi, S
Casula, P
Lambertenchi-Deliliers, G
Vespignani, M
Izzi, T
Coser, P
Corneo, G
Barbui, T
Citation: R. Bassan et al., Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractorydisease in T-lineage but not B-lineage acute lymphoblastic leukemia: firstresults from a phase II clinical study, HAEMATOLOG, 84(12), 1999, pp. 1088-1093
Authors:
Galli, M
Finazzi, G
Norbis, F
Marziali, S
Marchioli, R
Barbui, T
Citation: M. Galli et al., The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile, THROMB HAEM, 81(5), 1999, pp. 695-700
Authors:
Michiels, JJ
Kutti, J
Stark, P
Bazzan, M
Gugliotta, L
Marchioli, R
Griesshammer, M
van Genderen, PJJ
Briere, J
Kiladjian, JJ
Barbui, T
Finazzi, G
Berlin, NI
Pearson, TC
Green, AC
Fruchtmann, SM
Silver, RT
Hansmann, E
Wehmeier, A
Lengfelder, E
Landolfi, R
Kvasnicka, HM
Hasselbalch, H
Cervantes, F
Reilly, JT
Demory, JL
Gisslinger, H
Guardiola, P
Martyre, MC
Le Bousse-Kerdiles, MC
Thiele, J
Citation: Jj. Michiels et al., Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis, NETH J MED, 54(2), 1999, pp. 46-62
Authors:
Ringden, O
Labopin, M
Frassoni, F
Sanz, GF
Demeocq, F
Prentice, HG
Cahn, JY
Barbui, T
Meloni, G
Schaefer, UW
Reiffers, J
Gorin, NC
Citation: O. Ringden et al., Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft, BONE MAR TR, 24(4), 1999, pp. 389-396
Authors:
Barbui, T
Finazzi, G
Citation: T. Barbui et G. Finazzi, Clinical parameters for determining when and when not to treat essential thrombocythemia, SEM HEMATOL, 36(1), 1999, pp. 14-18
Authors:
Ruggeri, M
Tosetto, A
Rodeghiero, F
Finazzi, G
Barbui, T
Citation: M. Ruggeri et al., The management of 'low-risk' and 'intermediate-risk' patients with primarythrombocythaemia, BR J HAEM, 106(3), 1999, pp. 834-834
Authors:
Dotti, G
Garattini, E
Borleri, G
Masuhara, K
Spinelli, O
Barbui, T
Rambaldi, A
Citation: G. Dotti et al., Leucocyte alkaline phosphatase identifies terminally differentiated normalneutrophils and its lack in chronic myelogenous leukaemia is not dependenton p210 tyrosine kinase activity, BR J HAEM, 105(1), 1999, pp. 163-172
Authors:
Bassan, R
Lerede, T
Di Bona, E
Rambaldi, A
Rossi, G
Pogliani, E
Oriani, A
D'Emilio, A
Izzi, T
Lambertenghi-Deliliers, G
Corneo, G
Barbui, T
Citation: R. Bassan et al., Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia, BR J HAEM, 104(4), 1999, pp. 755-762
Authors:
Falanga, A
Marchetti, M
Evangelista, V
Manarini, S
Oldani, E
Giovanelli, S
Galbusera, M
Cerletti, C
Barbui, T
Citation: A. Falanga et al., Neutrophil activation and hemostatic changes in health donors receiving granulocyte colony-stimulating factor, BLOOD, 93(8), 1999, pp. 2506-2514
Authors:
Galli, M
Barbui, T
Citation: M. Galli et T. Barbui, Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome, BLOOD, 93(7), 1999, pp. 2149-2157
Authors:
Barbui, T
Finazzi, G
Barosi, G
Citation: T. Barbui et al., Chronic myeloid disorders, excluding CML, TEXTBOOK OF MALIGNANT HAEMATOLOGY, 1999, pp. 847-869
Authors:
Ruggeri, M
Finazzi, G
Tosetto, A
Riva, S
Rodeghiero, F
Barbui, T
Citation: M. Ruggeri et al., No treatment for low-risk thrombocythaemia: results from a prospective study, BR J HAEM, 103(3), 1998, pp. 772-777